Every material Form 8-K Hims & Hers Health has filed with the SEC since May 05, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Hims & Hers appointed Jonathan M. Franklin as principal accounting officer, effective October 9, 2026, replacing Irene Becklund, who resigned from the role. Franklin started as chief accounting officer on October 5, 2026, and joins from Rivian Automotive, where he was a vice president and corporate controller.
Jonathan M. Franklin, 43, started as chief accounting officer on October 5, 2026, and becomes principal accounting officer on October 9, 2026.
Franklin's compensation includes a $425,000 base salary, a $150,000 signing bonus, and restricted stock units with a $3,000,000 grant value.
Irene Becklund's resignation as principal accounting officer is effective alongside the appointment; she will advise the company under an agreement through July 10, 2027.
Hims & Hers reported second quarter 2026 revenue of $753.2 million, up 38% from a year earlier, and raised its full-year 2026 revenue guidance to $3.1 billion to $3.3 billion. The company swung to a net loss of $86.3 million from net income of $42.5 million in the prior-year quarter, and Adjusted EBITDA fell to $60.3 million from $82.2 million, so shareholders face higher revenue alongside lower profit.
Q2 2026 revenue was $753.2 million, up 38% year-over-year; subscribers reached 2,891 thousand, up 19%
Net loss was $86.3 million in Q2 2026 versus net income of $42.5 million in Q2 2025; gross margin fell to 64% from 76%
Adjusted EBITDA was $60.3 million versus $82.2 million a year earlier; Free Cash Flow was $(68.2) million
Full-year 2026 revenue guidance raised to $3.1 billion to $3.3 billion; Adjusted EBITDA guidance set at $275 million to $325 million
Hims & Hers Health said Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign effective October 9, 2026, and she has said the decision is not tied to any disagreement over accounting or financial reporting. The company will retain her in an advisory role from October 10, 2026 through July 10, 2027, which gives it continuity during the transition of its accounting leadership.
Irene Becklund informed the company of her resignation on July 13, 2026, effective October 9, 2026.
Becklund has been Chief Accounting Officer since April 2025 and Principal Accounting Officer since November 2021.
She has stated the resignation is not the result of any dispute over accounting principles, practices, or financial statements.
An advisory agreement effective October 10, 2026 keeps her supporting the company until July 10, 2027.
Hims & Hers subsidiaries XeCare LLC and Apostrophe Pharmacy LLC entered a Master Receivables Purchase Agreement with JPMorgan Chase Bank on July 1, 2026, allowing them to sell eligible receivables for cash, subject to a $400 million facility limit. The company also agreed to guarantee the sellers' performance under the agreement, though not the collectability of the receivables, and amended its credit agreement to permit the arrangement.
Facility limit for eligible receivables is $400 million, with an initial term of 364 days that may be extended.
The company guarantees the sellers' performance under the agreement but not receivable collectability or seller creditworthiness.
Amendment No. 4 to the Revolving Credit and Guaranty Agreement, dated June 26, 2026, adds a $400 million debt basket for this arrangement.
The filing does not disclose the purchase discount or any financial results tied to the arrangement.
Hims & Hers completed its acquisition of Eucalyptus, an Australia-based consumer health platform, and announced it on June 2, 2026. Under Amendment No. 3 to its revolving credit agreement, dated May 29, 2026, the company received a grace period to comply with covenants and representations affected by the acquisition. The filing does not disclose the purchase price.
Amendment No. 3 is dated May 29, 2026; JPMorgan Chase Bank, N.A. is administrative and collateral agent.
The amendment provides a grace period on credit agreement covenants and representations tied to the Eucalyptus acquisition, sets joinder obligations for material foreign subsidiaries, and increases downstream investment capacity in non-loan
The filing states that interest provisions, fees, covenants and events of default were otherwise unchanged.
Eucalyptus has more than 850,000 customers as of May 2026, and the company reiterated long-term targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.
Hims & Hers issued $402.5 million of senior unsecured convertible notes on May 21, 2026, under an indenture with U.S. Bank Trust Company as trustee. The notes do not bear regular interest and mature on June 1, 2032. Alongside the offering, the company paid approximately $36.7 million for capped call transactions meant to reduce potential dilution from conversions, but the notes add a $402.5 million debt obligation and could lead to issuance of up to 18,057,397 Class A shares.
$402.5 million aggregate principal of notes issued May 21, 2026, maturing June 1, 2032, with no regular interest.
Initial conversion price of approximately $29.53 per share; maximum of 18,057,397 Class A shares may be issued on conversion at the initial maximum conversion rate.
Capped call transactions cost approximately $36.7 million, with an initial cap price of approximately $50.15 per share, a 125.0% premium over the May 18, 2026 last reported sale price.
Hims & Hers reported first-quarter 2026 revenue of $608.1 million, up 4% from a year earlier, but swung to a net loss of $92.1 million from net income of $49.5 million in the same period of 2025. The company raised its full-year 2026 revenue guidance to $2.8 billion to $3.0 billion and set full-year Adjusted EBITDA guidance at $275 million to $350 million, which excludes the proposed Eucalyptus acquisition.
Q1 2026 Adjusted EBITDA was $44.3 million, down from $91.1 million, with margin at 7% versus 16%.
Gross margin fell to 65% from 73%, and United States revenue declined 8% to $529.9 million while Rest of the World revenue rose to $78.2 million.
Subscribers reached about 2.6 million at March 31, 2026, up 9% year over year.
Second-quarter 2026 guidance calls for revenue of $680 million to $700 million and Adjusted EBITDA of $35 million to $55 million.
Hims & Hers reported fourth-quarter and full-year 2025 results, with revenue up 59% for the year to $2.35 billion and full-year net income of $128.4 million. Fourth-quarter net income fell from $26.0 million a year earlier, and gross margin dropped to 72% from 77%. The company guided to 2026 revenue of $2.7 billion to $2.9 billion and Adjusted EBITDA of $300 million to $375 million, excluding the proposed Eucalyptus acquisition.
Q4 2025 revenue was $617.8 million, up 28% from $481.1 million; full-year revenue was $2.35 billion, up 59%.
Q4 2025 net income was $20.6 million versus $26.0 million in Q4 2024; full-year net income was $128.4 million versus $126.0 million.
Full-year 2025 Adjusted EBITDA was $318.0 million versus $176.9 million in 2024; Q4 free cash flow was $(2.6) million versus $59.5 million.
2026 guidance: first-quarter revenue of $600 million to $625 million and full-year revenue of $2.7 billion to $2.9 billion; guidance excludes the proposed Eucalyptus acquisition, expected to close mid-2026.
Hims & Hers agreed to acquire all issued capital of Australian digital health company Eucalyptus for up to about $1.15 billion, including upfront, deferred and earnout payments. The company may pay part of the deferred and earnout amounts in its Class A common stock, which would add shares outstanding, and closing is expected in the middle of 2026, subject to regulatory and other conditions.
Upfront payments of about $240 million are due at closing, with deferred payments of about $710 million and earnout payments of up to about $200 million.
Hims & Hers may settle up to about 60% of the deferred and earnout payments in Class A common stock at its discretion.
Closing is anticipated in the middle of fiscal year 2026 and is subject to regulatory approvals, key contract consents and other conditions.
The company said it expects to fund most of the transaction with existing cash and future U.S. operating cash flow.
Hims & Hers reported third quarter 2025 revenue of $599.0 million, up 49% from a year earlier, and Adjusted EBITDA of $78.4 million, up from $51.1 million. Net income fell to $15.8 million from $75.6 million, a year-earlier figure that included a $60.8 million tax benefit. The company narrowed its full-year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million.
Q3 2025 revenue was $599.0 million, up 49% from $401.6 million; subscribers reached 2,471 thousand, up 21%.
Q3 2025 net income was $15.8 million, compared with $75.6 million in Q3 2024, which included a $60.8 million tax benefit.
Q3 2025 Adjusted EBITDA was $78.4 million, up from $51.1 million; gross margin was 74%, down from 79%.
Full-year 2025 guidance was narrowed to $2.335 billion to $2.355 billion in revenue; Q4 2025 revenue guidance is $605 million to $625 million.
Hims & Hers Health said COO Nader Kabbani will move into a new advisory role effective November 2, 2025, continuing to provide strategic guidance through July 2026. Chief Commercial Officer Mike Chi will become Chief Operating Officer on the same date, and the company will consolidate operations, marketing, product and commercial functions under him and will not have a separate Chief Commercial Officer.
Nader Kabbani determined to step into an advisory role on September 28, 2025, effective November 2, 2025, through July 2026
Mike Chi, 46, joined the company in April 2021 and will become Chief Operating Officer effective November 2, 2025
The Compensation Committee plans to review Mr. Chi's compensation in light of his expanded responsibilities; no changes have been approved
The company will not have a separate Chief Commercial Officer after the transition
Hims, Inc., a subsidiary of Hims & Hers Health, signed a 15-year lease covering about 352,012 square feet at 9885 Innovation Campus Way in New Albany, Ohio, for office, research and development, laboratory, manufacturing and pharmaceutical dispensing use. The parent company guaranteed the subsidiary's lease obligations, and the filing gives initial annual base rent of $5,984,204, so the commitment is a long-term fixed cost for shareholders.
Lease dated September 1, 2025, with an initial term of 15 years and two five-year extension options
Initial annual base rent of $5,984,204, rising about 3.25% each year; rent payments begin April 1, 2026
Base rent is abated until April 1, 2026, and partly abated at $262,838.42 per month for five months after that
A letter of credit for $5,984,204 from JPMorgan Chase Bank secures the lease, and the parent executed a guaranty
Hims & Hers reported second-quarter 2025 revenue of $544.8 million, up 73% from a year earlier, and net income of $42.5 million, compared with $13.3 million in the second quarter of 2024. The company affirmed its full-year 2025 revenue and Adjusted EBITDA guidance and gave third-quarter outlook, but free cash flow was negative $69.4 million and gross margin fell to 76% from 81%.
Q2 2025 revenue was $544.8 million, up 73% from $315.6 million; subscribers reached 2,439 thousand, up 31%
Net income was $42.5 million and Adjusted EBITDA was $82.2 million, versus $13.3 million and $39.3 million a year earlier
Free cash flow was negative $69.4 million, compared with positive $47.6 million in Q2 2024
Full-year 2025 guidance affirmed: revenue of $2.3 billion to $2.4 billion and Adjusted EBITDA of $295 million to $335 million; Q3 revenue guidance is $570 million to $590 million
Hims & Hers Health issued $1.0 billion of senior, unsecured convertible notes maturing May 15, 2030, under an indenture dated May 13, 2025. The notes carry no regular interest, and the company also entered capped call transactions costing approximately $47.8 million that are expected to reduce potential dilution from conversions.
Notes: $1.0 billion aggregate principal, maturing May 15, 2030; no regular interest accrues
Initial conversion price of approximately $70.67 per Class A share; up to 19,455,200 shares issuable on conversion at the maximum rate
Capped call cost approximately $47.8 million; cap price initially $89.95 per share, a 75.0% premium over the May 8, 2025 closing price
Notes may be redeemed from May 19, 2028 under specified conditions; the company may settle conversions in cash, shares, or both
Hims & Hers reported first quarter 2025 revenue of $586.0 million, up 111% from a year earlier, and net income of $49.5 million, compared with $11.1 million. The company affirmed its full-year 2025 revenue guidance of $2.3 billion to $2.4 billion and raised its full-year Adjusted EBITDA guidance to $295 million to $335 million. Gross margin fell to 73% from 82%, and second-quarter revenue guidance of $530 million to $550 million was below the first-quarter result.
Q1 2025 revenue was $586.0 million, up 111% year over year; net income was $49.5 million versus $11.1 million; diluted EPS was $0.20 versus $0.05.
Adjusted EBITDA was $91.1 million in Q1 2025, compared with $32.3 million a year earlier.
Full-year 2025 Adjusted EBITDA guidance was raised to $295 million to $335 million; full-year revenue guidance of $2.3 billion to $2.4 billion was affirmed.
The company set 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Hims & Hers Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →